Nivolumab (Genetical Recombination) 240mg 24mL/vial 1,283cases,and 16 other contracts

2026-11-03

Official in charge of disbursement of the procuring entity : Takashi Wada, President, Kanazawa University Classification of the products to be procured : Nature and quantity of the products to be purchased : A Nivolumab (Genetical Recombination) 240mg 24mL/vial 1,283cases B Pembrolizumab (Genetical Recombination) 100mg 4mL/vial 3,135cases C Onasemnogene Abeparvove Per patient 2cases D Tisagenlecleucel Per patient 2cases E Lisocabtagene Maraleucel Per patient 8cases F Atezolizumab (Genetical Recombination) 1,200mg 20mL/vial 420cases G Idecabtagene Vicleucel Per patient 2cases H Human (allogeneic) mesenchymal stem cells derived from bone marrow Once 2cases I Ravulizumab (Genetical Recombination) 300mg 3mL/vial 264cases J Axicabtagene Ciloleucel Per patient 6cases K Human (allogeneic) mesenchymal stem cells derived from bone marrow 10.8mL/bag 84cases L Durvalumab (Genetical Recombination) 500mg 10mL/vial 1,463cases M Vutrisiran Sodiumu 25mg 0.5mL/syringe 38cases N Neltependocel Per patient 12cases O Darvadstrocel 6mL/4vial 2cases P Blinatumomab (Genetical Recombination) 35μg 10mL/vial 648cases Q Teprotumumab (Genetical Recombination) 500mg/vial 245cases Delivery period : From 0 April, 202 through 3 March, 202 Delivery place : Kanazawa University Hospital Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall : A not come under Article 3 and 3 of the Regulation concerning the Contract for Kanazawa University, B have the Grade A, Grade B, Grade C or Grade D qualification during fiscal 202 in the Tokai・Hokuriku area in sales of product for participating in tenders by Single qualification for every ministry and agency, C prove to have obtained the first-class license for selling drugs in accordance with the Pharmaceutical and Medical Device Act, D prove to have the ability to deliver the products, required by this notice, on the date and to the place specified by the Obligating Officer, E meet the qualification requirements which President, Kanazawa University may specify in accordance with Article 3 paragraph of the Regulation, F not be currently under a suspension of business order as instructed by President, Kanazawa University. Time limit of tender : 1 : 0 1 March, 202 Contact point for the notice : Tatsuya Kawada, Procurement management Section, Hospital Management Division, Hospital Department, Kanazawa University, 13- Takara-machi Kanazawa-shi 920-864 Japan, TEL 076-265-206 ⑼ Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents.

Japan

2026-03-26